Document Detail

Content of luteinizing hormone-releasing factor in the human placenta.
MedLine Citation:
PMID:  339717     Owner:  NLM     Status:  MEDLINE    
Immunoreactive luteinizing hormone-releasing factor (LRF) was quantitated in the human placenta. It was found that the total placental content as well as the content per milligram of placental tissue varied with the stages of gestation. The fetal sex did not affect the LRF production. These studies establish that the placenta contains large amounts of LRF, immunologically identical to hypothalamic LRF.
T M Siler-Khodr; G S Khodr
Related Documents :
8761967 - Arachidonate metabolism in human placenta, fetal membranes, decidua and myometrium: lip...
10459437 - Immunohistochemical detection of apoptosis in the human term and post-term placenta.
416297 - Placenta extrachorialis in the stumptailed macaque (macaca arctoides).
1153897 - Morphological studies on the fetal membranes of the normal singleton foal at term.
1998007 - Metabolism of progesterone in the canine feto-placental unit.
15713717 - Sildenafil citrate (viagra) enhances vasodilatation in fetal growth restriction.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  130     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  1978 Jan 
Date Detail:
Created Date:  1978-02-23     Completed Date:  1978-02-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  216-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Gestational Age
Gonadotropin-Releasing Hormone / analysis*
Placenta / analysis*
Sex Factors
Reg. No./Substance:
33515-09-2/Gonadotropin-Releasing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cervical-vaginal flora of immunosuppressed renal transplant patients.
Next Document:  A two-year trial of intraocular lenses at the Wilmer Institute.